TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31888122

Group type: EXPERIMENTAL
Intervention: Fructose hydrogen breath test (H2BT)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Lactose hydrogen breath test (H2BT)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Diagnostic elimination diet
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Carbohydrate malabsorption diagnosis
Number of subjects: 253
Study: 28356068

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control treatment (deflated cuff)
Number of subjects: 46
Study: 26921645

Group type: EXPERIMENTAL
Intervention: Electrical Pudendal Nerve Stimulation (EPNS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Electromyogram biofeedback (BF)‐assisted pelvic floor muscle training (PFMT) plus transvaginal electrical stimulation (TES)
Number of subjects: 42
Study: 24442926

Group type: EXPERIMENTAL
Intervention: CAM2028-benzydamine
Number of subjects: 38

Group type: COMPARATOR
Intervention: CAM2028-control
Number of subjects: 38
Study: 22845633

Group type: EXPERIMENTAL
Intervention: Contact isolation application
Number of subjects: 117

Group type: COMPARATOR
Intervention: Non-isolated patients
Number of subjects: 117
Study: 20859673

Group type: EXPERIMENTAL
Intervention: Dietary acrylamide intake (highest quintile)
Number of subjects: 27111

Group type: COMPARATOR
Intervention: Dietary acrylamide intake (lowest quintile)
Number of subjects: 27111
Study: 17437877

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17% EDTA + 2.5% NaOCl
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined treatments (treatment solution with subsequent NaOCl application)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17% EGTA + 2.5% NaOCl
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single treatments
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Treatment time of 5 minutes
Number of subjects: 100
Study: 15756615

Group type: EXPERIMENTAL
Intervention: ACL reconstruction using the central third of the patellar tendon
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study: 11506819

Group type: EXPERIMENTAL
Intervention: Quercetin (30 mg per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9743394

Group type: EXPERIMENTAL
Intervention: 5 microg sufentanil plus 30 microg clonidine
Number of subjects: 53

Group type: COMPARATOR
Intervention: 5 microg sufentanil
Number of subjects: 53
Study: 8064101

Group type: EXPERIMENTAL
Intervention: Resistive training
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combined resistive/balance training
Number of subjects: 110

Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (health-related discussion sessions)
Number of subjects: 110
Study: 2538094

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine with 8.4% sodium bicarbonate
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2-chloroprocaine with normal saline (control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Subsequent bupivacaine analgesia
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bupivacaine dosage during first stage of labor
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pain scores over time
Number of subjects: 62
Study: 31028957

Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg weekly)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 28011288

Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen
Number of subjects: 4317

Group type: COMPARATOR
Intervention: DRSP/EE (3 mg/30 μg) in a 21/7-day regimen
Number of subjects: 4317

Group type: EXPERIMENTAL
Intervention: NOMAC/E2
Number of subjects: 4317

Group type: COMPARATOR
Intervention: DRSP/EE
Number of subjects: 4317
Study: 25066875

Group type: EXPERIMENTAL
Intervention: Prostate capsule sparing cystectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nerve sparing cystectomy
Number of subjects: 40
Study: 23365126

Group type: EXPERIMENTAL
Intervention: Breast-feeding (BRF)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Formula-feeding (FOF)
Number of subjects: 48
Study: 21980799

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a high-dose 6-grass pollen preparation
Number of subjects: 46
Study: 19262499

Group type: EXPERIMENTAL
Intervention: Salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulfate)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Regular salt (100% sodium chloride)
Number of subjects: 600
Study: 17924020

Group type: EXPERIMENTAL
Intervention: Fluor protector every six months (experimental group A, n=207, 335 teeth)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement as pit and fissure sealant (experimental group B, n=205, 327 teeth)
Number of subjects: 622

Group type: COMPARATOR
Intervention: No treatment (control group, n=210, 354 teeth)
Number of subjects: 622
Study: 15065832

Group type: EXPERIMENTAL
Intervention: Iron lung ventilation (ILV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 44
Study: 10702458

Group type: EXPERIMENTAL
Intervention: Propofol infusion (100 microg. kg(‐1). min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane (1.0%, end‐tidal) with nitrous oxide 66%
Number of subjects: 60
Study: 8922197

Group type: EXPERIMENTAL
Intervention: CVD/Bio (cisplatin, vinblastine, DTIC followed by IL-2 and IFN-alpha)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Bio/CVD (IL-2 and IFN-alpha followed by cisplatin, vinblastine, DTIC)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sequential biochemotherapy (CVD followed by IL-2 and IFN-alpha)
Number of subjects: 102

Group type: COMPARATOR
Intervention: CVD (cisplatin, vinblastine, DTIC alone)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: CVD/Bio
Number of subjects: 102
Study: 2861876

Group type: EXPERIMENTAL
Intervention: Sulphasalazine 1.5 g/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sulphasalazine 3 g/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sulphasalazine > 40 mg/kg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serum levels of sulphasalazine and its metabolites
Number of subjects: 60
Study: 30292919

Group type: EXPERIMENTAL
Intervention: Skin tests (prick and intradermal tests) for taxanes
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Graded challenge
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Desensitization schedule
Number of subjects: 84

Group type: COMPARATOR
Intervention: Skin tests in control group
Number of subjects: 84
Study: 28326925

Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture (ipsilateral)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture (contralateral)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo electroacupuncture (ipsilateral)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo electroacupuncture (contralateral)
Number of subjects: 24
Study: 26009799

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT; 100 μg) introduced in a single dose after three hours from the beginning of TK analgesia (TKF treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketorolac (0.86 mg/kg/day) and tramadol (7.2 mg/kg/day) (TK treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT; 100 μg)
Number of subjects: 0
Study: 24369953

Group type: EXPERIMENTAL
Intervention: Mammographic screening (two-view film-screen mammography)
Number of subjects: 86276

Group type: COMPARATOR
Intervention: Review of interval cancers by offsite radiologists
Number of subjects: 86276
Study: 22672794

Group type: EXPERIMENTAL
Intervention: I-ONE therapy (PEMFs) for 4 hours/day for 60 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: I-ONE therapy (PEMFs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 30
Study: 19572829

Group type: EXPERIMENTAL
Intervention: Adaptive TDT (aTDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MAX test
Number of subjects: 0

Group type: COMPARATOR
Intervention: CLRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal TDT-type test
Number of subjects: 0
Study: 17300600

Group type: EXPERIMENTAL
Intervention: 0.45 ms pulse width
Number of subjects: 19

Group type: COMPARATOR
Intervention: 40 ms pulse width
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both pulse widths (0.45 ms and 40 ms)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both pulse widths
Number of subjects: 19
Study: 15013307

Group type: EXPERIMENTAL
Intervention: MM-Cept 500 mg tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cellcept 500 mg tablets
Number of subjects: 0
Study: 12888152

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 14564615

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 34

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 34
Study: 8930036

Group type: EXPERIMENTAL
Intervention: Stapled oesophagogastric anastomosis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Handsewn oesophagogastric anastomosis
Number of subjects: 100
Study: 1873002

Group type: EXPERIMENTAL
Intervention: 12 g/day SF
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 24 g/day SF
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 6 g/day SF
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All three SF doses
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sodium-sensitive patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sodium-insensitive patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Seaweed preparation
Number of subjects: 62
Study: 6126067

Group type: EXPERIMENTAL
Intervention: Estazolam (1 + 1 + 4 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 2859069

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 36
Study: 31897941

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (50 ml per day for 10 days, followed by two additional treatment cycles with 10 ml per day for 10 days)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Physiological saline solution (placebo)
Number of subjects: 142
Study: 29551172

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (50 mg capsules, three times daily for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules (three times daily for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 0
Study: 26669919

Group type: EXPERIMENTAL
Intervention: Ixekizumab 160 mg administered at weeks 16, 18, and 20, then every 4 weeks through Week 64
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Ixekizumab treatment
Number of subjects: 390
Study: 24754961

Group type: EXPERIMENTAL
Intervention: Individual training in a structured multimodality training curriculum
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pair training in a structured multimodality training curriculum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no training between tests)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Individual training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pair training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cognitive tests and questionnaires
Number of subjects: 100
Study: 23778432

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion (when initial hemoglobin > 10 g/dL)
Number of subjects: 1158
Study: 20400258

Group type: EXPERIMENTAL
Intervention: Osteoporosis school programme (four classes of 8‐12 participants over four weeks)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Osteoporosis school programme
Number of subjects: 300
Study: 18082007

Group type: EXPERIMENTAL
Intervention: PALS program (intervention group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 14
Study: 15871011

Group type: EXPERIMENTAL
Intervention: NIPSV
Number of subjects: 36

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 36
Study: 12764217

Group type: EXPERIMENTAL
Intervention: Weight reduction surgery
Number of subjects: 2231

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Weight change (both groups)
Number of subjects: 2231
Study: 11016286

Group type: EXPERIMENTAL
Intervention: Active laser treatment (50 mW, 830 nm, 10 minutes per session)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study: 8851530

Group type: EXPERIMENTAL
Intervention: Water temperature of 30 degrees C
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Water temperature of 38 degrees C
Number of subjects: 6

Group type: COMPARATOR
Intervention: No water in the bath tub (control)
Number of subjects: 6
Study: 1485782

Group type: EXPERIMENTAL
Intervention: Sodium alginate (alginic acid)
Number of subjects: 76
Study: 6691244

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg/min intravenously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31571834

Group type: EXPERIMENTAL
Intervention: Test FDC tablet containing 10 mg melitracen and 0.5 mg flupentixol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference FDC tablet containing 10 mg melitracen and 0.5 mg flupentixol
Number of subjects: 48
Study: 30376823

Group type: EXPERIMENTAL
Intervention: Weekly cell phone counselling and daily text messages
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Routine healthcare services
Number of subjects: 1036
Study: 27401319

Group type: EXPERIMENTAL
Intervention: SLIT with probiotic
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SLIT with vitamin D
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SLIT alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no SLIT)
Number of subjects: 100
Study: 25271822

Group type: EXPERIMENTAL
Intervention: Dexamphetamine sulfate (0.3 mg/kg) administered intravenously
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 38
Study: 22119172

Group type: EXPERIMENTAL
Intervention: Free delayed recall after 4 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Free delayed recall after 1 week
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard 30-min retention interval
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI) assessment
Number of subjects: 73
Study: 20149145

Group type: EXPERIMENTAL
Intervention: Early intervention (EI) consisting of seven in-hospital sessions prior to discharge and four home visits.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (CG) - no specific intervention mentioned.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Early intervention (EI)
Number of subjects: 146
Study: 17968992

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (2 mg/kg/day in 3 divided doses for 3 days)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 16221106

Group type: EXPERIMENTAL
Intervention: Losartan plus conventional therapy (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (CT) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan plus CT
Number of subjects: 0
Study: 12602521

Group type: COMPARATOR
Intervention: Oral and parenteral L-ornithine-L-aspartate (OA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral L-ornithine-L-aspartate (OA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous L-ornithine-L-aspartate (OA)
Number of subjects: 0
Study: 9531901

Group type: COMPARATOR
Intervention: Conventional method (group I, n=29)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Simplified technique (group II, n=30)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (group III, n=29)
Number of subjects: 95
Study: 7647144

Group type: EXPERIMENTAL
Intervention: Prifinium bromide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hyoscine N-butylbromide
Number of subjects: 30
Study: 2491458

Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole daily
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole daily
Number of subjects: 171
Study: 590310

Group type: EXPERIMENTAL
Intervention: 14C‐aminopyrine 9 mg/kg (pharmacological dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Tracer amount of 14C‐aminopyrine
Number of subjects: 9
Study: 30842115

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28220512

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir with ribavirin
Number of subjects: 49
Study: 25989213

Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FFRD) alone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FFRD) and mini-implants (FMI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 43
Study: 24355657

Group type: EXPERIMENTAL
Intervention: Effervescent powder (EP)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No effervescent powder (non-EP)
Number of subjects: 92
Study: 22743148

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m²
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mitoxantrone 12 mg/m²
Number of subjects: 90
Study: 19627577

Group type: EXPERIMENTAL
Intervention: Inappropriate medication use (long-acting benzodiazepines)
Number of subjects: 6343

Group type: EXPERIMENTAL
Intervention: Inappropriate medication use (other inappropriate psychotropics)
Number of subjects: 6343

Group type: EXPERIMENTAL
Intervention: Inappropriate medication use (medications with anticholinergic properties)
Number of subjects: 6343

Group type: EXPERIMENTAL
Intervention: Occasional or regular use of short- or intermediate-acting benzodiazepines
Number of subjects: 6343

Group type: EXPERIMENTAL
Intervention: Long-acting benzodiazepines
Number of subjects: 6343
Study: 17560254

Group type: EXPERIMENTAL
Intervention: Routine oral calcitriol and calcium carbonate postoperatively (Group 1)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Calcium carbonate postoperatively at the discretion of the primary surgeon (Group 2)
Number of subjects: 86
Study: 15277163

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (Bic)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sodium lactate (Lac)
Number of subjects: 11
Study: 11555433

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets
Number of subjects: 1961

Group type: COMPARATOR
Intervention: No net (control group)
Number of subjects: 1961
Study: 9331015

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8‐16 mg once‐daily
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 8176802

Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD CPR)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 130
Study: 3319731

Group type: EXPERIMENTAL
Intervention: Topical minoxidil 2%
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Topical minoxidil 2% and Placebo
Number of subjects: 225
Study: 29800250

Group type: EXPERIMENTAL
Intervention: LV rehabilitation (low-vision devices with therapy)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Basic LV services (low-vision devices without therapy)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: LV rehabilitation
Number of subjects: 323
Study: 25529391

Group type: EXPERIMENTAL
Intervention: 12 week rehabilitation programme including cancer-related education, progressive muscle relaxation, and emotional support
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 47
Study: 24530385

Group type: EXPERIMENTAL
Intervention: Ketoprofen tape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (shower after application)
Number of subjects: 0
Study: 22854954

Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS) + laparoscopy-assisted radical distal gastrectomy (LADG)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Laparoscopy-assisted radical distal gastrectomy (LADG)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS) + open distal gastrectomy (ODG)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 88
Study: 20332484

Group type: EXPERIMENTAL
Intervention: Surgery plus 5-fluorouracil (5-FU)-based adjuvant chemotherapy
Number of subjects: 1389

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1389
Study: 17070962

Group type: COMPARATOR
Intervention: Cisplatin (50mg/m² i.v.) plus Gemcitabine (1250mg/m² i.v.)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Cisplatin (50mg/m² i.v.) plus Gemcitabine (1250mg/m² i.v.) plus Vinorelbine (25mg/m² i.v.)
Number of subjects: 154
Study: 15806211

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide (BUD) 200 microg twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral choline (tricholine citrate, TRI) 500 mg thrice daily
Number of subjects: 60
Study: 12542101

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10% carbamide peroxide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7822663

Group type: EXPERIMENTAL
Intervention: MK-0591 (3 oral doses of 250 mg each at 24, 12, and 1.5 hours before allergen inhalation)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2793717

Group type: EXPERIMENTAL
Intervention: Metabolic alkalosis induced by oral administration of NaHCO3
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 8
Study: 33495

Group type: EXPERIMENTAL
Intervention: Pirenzepin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28